To explore if activated JAK1/2 could serve as attractive therapeutic targets for ICB resistance, we treated melanoma-bearing mice with Ruxolitinib (Ruxo), an FDA-approved JAK1/2 inhibitor for myeloproliferative neoplasms (MPN) and other pathologies. Here, JAK1 is linked to myeloproliferative neoplasm.